-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
news
newsSage and Biogen announced today that their GABA receptor modulator Zuranolone achieved primary endpoints in a Phase 3 clinical trial called CORAL
Drug source analysis
Drug source analysisZuranolone is a neurosteroidal GABA-A receptor allosteric modulator that can simultaneously modulate synaptic and outer synaptic GABA receptors by binding to different binding sites of traditional GABA receptor ligands such as BZD and Z-drugs , and therefore may have anticonvulsant, antidepressant, and therapeutic activity in senile degenerative diseases such as AD in addition to hypnosis
Major depression is a serious unmet medical need, and a major advantage of Zuranolone is its rapid onset of action
HAMD-17 consists of 17 indicators, including three categories of insomnia and two categories of anxiety
Consistent with the mechanism of GABA agonists, the main side effects of this product are drowsiness and dizziness, which are said to be nothing compared to the side effects of existing antidepressants